This activity is expired and is no longer available for CME credit.


Intravitreal Interventions – Volume 3, Number 2

Author(s)/Faculty: Carmen A. Puliafito, MD, MBA; Harry W. Flynn Jr., MD; Peter K. Kaiser, MD ; Amol D. Kulkarni, MD; Ingrid U. Scott, MD, MPH; Charles C. Wykoff, MD, PhD
Release Date: 9/1/2014Expiration Date: 9/1/2015
Credit Type: CMENumber of Credits: 0
Content Type: MonographProvider:
Diabetic macular edema (DME) and macular edema associated with retinal vein occlusions (RVOs) are common vision-threatening retinal vascular disorders that historically have been treated with laser photocoagulation. Since the advent of intravitreal corticosteroids and anti-vascular endothelial growth factor agents, laser therapy has become less prevalent and pharmacologic agents, devices, and delivery systems have evolved. Joining ranibizumab, 2 medications previously indicated for macular edema due to some RVOs were approved by the FDA this summer for the treatment of certain patients with DME. In this issue of Intravitreal Interventions, experts explore current management strategies for DME, RVO, and neovascular age-related macular degeneration, including utilization of newly approved agents. An expert interview discusses use of imaging in diagnosis and treatment of these diseases.